Key points are not available for this paper at this time.
With several candidate dengue vaccines under development, this is an important time to help stakeholders (e. g. , policy makers, scientists, clinicians, and manufacturers) better understand the potential economic value (cost-effectiveness) of a dengue vaccine, especially while vaccine characteristics and strategies might be readily altered. We developed a decision analytic Markov simulation model to evaluate the potential health and economic value of administering a dengue vaccine to an individual (≤ 1 year of age) in Thailand from the societal perspective. Sensitivity analyses evaluated the effects of ranging various vaccine (e. g. , cost, efficacy, side effect), epidemiological (dengue risk), and disease (treatment-seeking behavior) characteristics. A ≥ 50% efficacious vaccine was highly cost-effective < 1× per capita gross domestic product (GDP) (4, 289) up to a total vaccination cost of 60 and cost-effective < 3× per capita GDP (12, 868) up to a total vaccination cost of 200. When the total vaccine series was 1. 50, many scenarios were cost saving.
Lee et al. (2011) studied this question.